SCHEMBL904672

SCHEMBL904672

CCOC(=O)c1ccc2c(cnn2CC)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.48
RAB9A P51151 3/20 0.48
ALDH1A1 P00352 2/20 0.48
PPARG P37231 1/20 0.48
NCOA2 Q15596 1/20 0.48
NCOA1 Q15788 1/20 0.48
CA12 O43570 2/20 0.48
CA1 P00915 2/20 0.48
CA2 P00918 2/20 0.48
CA7 P43166 2/20 0.48
CA9 Q16790 2/20 0.48
CA14 Q9ULX7 2/20 0.48
NPC1 O15118 3/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
EGFR P00533 1/20 0.46
ERBB2 P04626 1/20 0.46
NLRP3 Q96P20 1/20 0.46
SIRT2 Q8IXJ6 1/20 0.45
SIRT1 Q96EB6 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7427872 0.88 KMO (0.48) MAPTRAB9AALDH1A1PPARGNCOA2
SCHEMBL20594117 0.87 KDM4E (0.54) ALDH1A1CA12CA1CA2CA7
SCHEMBL4957912 0.87 HTR2A (0.46) MAPTRAB9AALDH1A1PPARGNCOA2
SCHEMBL28264534 0.86 PLA2G4A (0.43) ALDH1A1MEN1KMT2ANPSR1KDM4E
SCHEMBL7426302 0.86 EGFR (0.45) MAPTRAB9AALDH1A1PPARGNCOA2
SCHEMBL7425784 0.86 KMO (0.60) MAPTRAB9AALDH1A1PPARGNCOA2
SCHEMBL4959328 0.86 MAOA (0.43) MAPTRAB9AALDH1A1PPARGNCOA2
SCHEMBL7428104 0.85 PLA2G4A (0.46) MAPTRAB9AALDH1A1PPARGNCOA2
SCHEMBL8684617 0.85 MAOA (0.43) MAPTRAB9AALDH1A1PPARGNCOA2
SCHEMBL3436319 0.84 CCNC (0.49) MAPTRAB9AALDH1A1PPARGNCOA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2594555-B1 HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR ASKA PHARM CO LTD (JP) 2018-03-07 EP disclosed
US-9200008-B2 Heterocyclic compound and p27Kip1 degradation inhibitor ASKA PHARMACEUTICAL CO., LTD. (JP) 2015-12-01 US disclosed
US-8829026-B2 Sulfamoyl benzoic acid heterobicyclic derivatives as TRPM8 antagonists RAQUALIA PHARMA INC. (JP) 2014-09-09 US disclosed
US-20130210858-A1 SULFAMOYL BENZOIC ACID HETEROBICYCLIC DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2013-08-15 US disclosed
EP-2594555-A1 HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR ASKA Pharmaceutical Co., Ltd. (JP) 2013-05-22 EP disclosed
US-20130079306-A1 HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-28 US disclosed
WO-2012042915-A1 SULFAMOYL BENZOIC ACID HETEROBICYCLIC DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079306-A1 HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR CDKN1A, SKP2, CCNI MAPT 4033/4885RAB9A 2990/4885ALDH1A1 1594/4885
US-20130210858-A1 SULFAMOYL BENZOIC ACID HETEROBICYCLIC DERIVATIVES AS TRPM8 ANTAGONISTS TRPM8, TRPM6, TRPM5 MAPT 2629/4885RAB9A 1285/4885ALDH1A1 2692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.